



## **Celgene *Innovation Impact Award* Grants Support Efforts to Advance Blood Cancer Research Priorities and Lung Cancer Screening Adoption**

Celgene Corporation is proud to announce the two recipients of Celgene's inaugural *Innovation Impact Awards*: The Aplastic Anemia & Myelodysplastic Syndromes International Foundation (AA&MDSIF) and the Lung Cancer Alliance.



Celgene's *Innovation Impact Awards* program recognizes effective, innovative and successful initiatives in one of two therapeutic areas: hematology or oncology. The program aims to recognize the achievements of U.S.-based not-for-profit organizations addressing the needs of patients, caregivers and healthcare providers in today's challenging healthcare environment. Each award winner will receive a \$100,000 cash grant and be invited to participate in an *Innovation Experience* workshop.

"We are delighted to announce The Aplastic Anemia & MDS International Foundation and Lung Cancer Alliance as the recipients of our first annual *Innovation Impact Awards*," said Joel Beetsch, PhD, Vice President of Patient Advocacy at Celgene. "Innovation is at the core of everything we do at Celgene. The *Innovation Impact Awards* not only recognize the significant contributions of patient and professional organizations to patient treatment and care, but also broaden the impact of the award-winning programs by helping sustain, expand, and replicate those innovative initiatives."

### *Hematology Innovation Impact Award*

The Aplastic Anemia & MDS International Foundation received the hematology *Innovation Impact Award* for the MDS Clinical Research Consortium. AA&MDSIF has historically been very successful in developing research approaches and solutions for patients with these blood disorders where the bone marrow fails to make healthy blood cells. The MDS Clinical Research Consortium will work with prominent U.S. MDS research centers to optimize the research process by articulating pressing research questions in MDS and identify creative, innovative, and collaborative ways to answer them.

"Even from the earliest stages of development, we believed that the MDS Clinical Research Consortium was an innovative, game changing project that was perfectly aligned with our strategic plan. It is exciting—and humbling—to see that others are seeing it in the same way. We are very pleased and honored to be selected for this new and prestigious award. We deeply appreciate the support of the Edward P. Evans Foundation and our six Consortium partners who have made this program possible and for the hope it brings to patients and families for new treatments and a cure for MDS. "

John Huber, Executive Director, AA&MDSIF

### *Oncology Innovation Impact Award*

The Lung Cancer Alliance (LCA) received the oncology *Innovation Impact Award* for the “National Framework for Excellence in Lung Cancer Screening and Continuum of Care” initiative. LCA convened thought leaders from all fields related to lung cancer in 2012 to devise the “National Framework”, which has since been adopted by more than 100 medical facilities nationwide and endorsed by numerous professional societies. Funding from the award will help support efforts to educate the at-risk public through an award winning awareness campaign, encouraging more medical facilities to adopt the National Framework and implement its best practices and guidelines, and improving and expanding lung cancer screening.

“We are absolutely honored and thrilled to receive this prestigious award. We thank Celgene and the award committee for acknowledging the lifesaving impact of our National Framework of Excellence for Lung Cancer Screening and Continuum of Care. This means so much to our staff, the more than 100 screening centers of excellence following the Framework and most importantly, for those individuals diagnosed with or at risk for lung cancer. This is a proud moment and renews our commitment to saving lives through helping the community, advancing screening and accelerating lung cancer research.”

Laurie Fenton Ambrose, President and CEO, Lung Cancer Alliance

The submissions for this year’s *Innovation Impact Awards* represented a wide range of approaches to support the hematology and oncology communities. The Aplastic Anemia & MDS International Foundation and Lung Cancer Alliance programs included a high level of innovation, strong vision, and plans to improve patient treatment, care, and survivorship.

The competitive *Innovation Impact Awards Program* was open to U.S.-based not-for-profit patient and professional organizations working in hematology or oncology. Eligible programs were those having demonstrable impact on the lives of patients, family members, caregivers, and/or the medical professionals who provide treatment and care. Those programs had to address a defined challenge faced by the target population. An independent judging panel that included innovation, healthcare, and advocacy experts identified the two award recipients from a pool of applicants. For more information about the Awards visit <http://www.innovationimpact.com>.

### **About the Aplastic Anemia & MDS International Foundation**

The Aplastic Anemia & MDS International Foundation is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.

### **About the Lung Cancer Alliance**

Lung Cancer Alliance is the only national nonprofit organization dedicated solely to patient support and advocacy for those living with or at risk for lung cancer. LCA is committed to leading the movement to reverse decades of stigma and neglect by empowering those with or at risk for the disease, elevating awareness and changing health policy.